SHIRE PLC SHPG Cash Flow

Shire plc (SHPG)

CashFlow / TTM

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Dec'09	Sep'09	Jun'09	Mar'09
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
4,808	4,822	4,447	4,271	1,623	685	283	327	150	990	1,312	1,303	3,195	3,222	3,585	3,405	1,297	1,095	830	665	643	592	571	745	958	924	892	865	775	678	633	588	597	560	443	491	0	0	0
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	0	0	0
Depreciation and amortization
2,428	2,439	2,401	2,264	2,232	2,078	1,784	1,466	1,057	775	685	637	557	494	433	407	402	378	344	324	306	307	310	308	314	314	304	294	278	258	254	255	262	261	259	250	0	0	0
Share based compensation
150	155	163	174	208	230	352	318	299	250	103	100	89	85	86	97	100	96	87	77	77	80	81	87	86	84	82	75	72	70	63	62	59	59	64	65	0	0	0
Amortization of deferred financing fees
-	-	-	-	-	-	-	125	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of PP&E
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of non-current investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11	11	11	11	55	0	0	0
Gain on sale of product rights
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	87	45	45	15	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Expense related to the unwind of inventory fair value adjustments
100	161	300	747	709	1,449	1,585	1,118	1,105	308	32	31	0	0	0	-	90	72	38	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in deferred taxes
2,509	2,828	2,831	2,916	440	558	720	594	566	448	224	198	255	119	16	14	302	345	332	349	11	13	36	58	31	56	77	14	76	56	25	15	-37	-5	80	98	0	0	0
Change in fair value of contingent consideration
-76	-18	-143	-120	-190	-203	3	-11	-11	-60	140	149	208	219	42	-14	104	166	98	159	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of PP&E and intangible assets
291	389	427	289	0	0	0	-	-	-	-	-	-	-	-	190	188	188	185	19	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill impairment charge
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198	7	7	7	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other, net
50	13	-39	-55	-95	-70	-75	-31	-58	17	16	0	67	42	25	27	-31	-26	-11	-11	-1	-2	-13	-7	-12	-22	-15	-16	-20	-17	-8	-9	-20	-9	-12	-14	0	0	0
Equity in losses/(earnings) of equity method investees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	5	2	3	1	1	0	1	-0	0	2	2	4	3	3	1	-1	-0	-1	-0	0	0	0
Changes in operating assets and liabilities:
Increase in accounts receivable
548	432	744	487	592	702	636	701	334	307	227	211	262	113	73	66	25	83	174	148	170	102	-36	-22	34	55	124	134	99	126	178	114	193	213	72	212	0	0	0
(Decrease)/increase in sales deduction accrual
197	294	579	314	274	279	232	288	105	126	195	97	179	38	12	107	97	243	203	177	115	55	32	42	70	42	103	80	99	134	188	222	91	171	77	134	0	0	0
Increase in inventory
205	143	33	145	273	311	375	255	269	142	73	63	31	51	28	25	12	-5	26	36	46	75	92	88	103	100	76	64	46	38	46	58	68	76	53	38	0	0	0
Decrease in prepayments and other assets
-55	85	69	-81	61	120	162	198	50	-35	27	-37	-178	-208	-159	-42	104	131	73	60	103	113	93	14	36	-9	24	36	-44	-29	17	40	28	18	-25	-30	0	0	0
Decrease/(increase) in other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Decrease in accounts payable and other liabilities
-213	-268	-27	-526	-251	-166	104	621	367	491	-122	109	154	110	228	5	46	83	15	67	-7	-58	73	136	164	101	32	-10	-34	-8	69	25	53	96	-37	38	0	0	0
Returns on investment from joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	0	0	0
Cash flows used in discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	0	0	0
Net cash provided by operating activities
4,327	4,524	4,807	4,256	3,890	3,360	2,728	2,658	2,267	2,303	2,164	2,337	4,130	4,162	4,543	4,228	2,283	2,124	1,548	1,463	1,224	1,079	1,286	1,382	1,420	1,310	1,128	1,073	1,007	970	970	954	848	840	629	626	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of subsidiary undertakings and businesses, net of cash acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Purchases of PP&E
-	0	764	-	-	860	809	648	449	249	144	114	0	0	0	-	23	7	-23	10	0	0	0	-	-	-	12	10	10	7	5	2	0	0	0	-	-	-	-
Acquisition of business, net of cash acquired
-	-	-	-	-	-	-	17,476	17,476	17,780	6,046	5,553	5,553	5,335	5,539	4,104	4,104	4,018	3,915	227	227	227	174	97	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of PP&E
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	149	150	163	179	194	200	213	329	326	346	360	256	254	0	0	0
Proceeds from sale of investments
-	-	-	-	-	-	-	-	-	-	-	85	67	68	65	57	57	56	46	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Movements in restricted cash
-	-	-	-	-	-	-	-62	-84	-54	-47	32	48	40	37	32	38	16	13	5	-2	3	4	-3	-2	-7	-16	-6	-559	-5	4	-6	540	-8	-9	3	0	0	0
Purchases of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43	43	48	27	5	0	0	0	-	-	-	-	7	0	0	0
Proceeds received on sale of product rights
-	-	-	-	-	-	-	-	-	-	-	-	18	83	82	127	126	61	62	19	19	17	17	17	16	15	17	12	0	0	0	-	-	-	-	-	-	-	-
Proceeds from capital expenditure grants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-
Other, net
-	-	-	-	-	-	-	-	-	-	-	-	18	17	14	21	24	12	19	12	0	0	0	-	-	-	109	106	94	0	0	2	0	0	0	-	-	-	-
Returns from equity investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-1	0	0	0	0	-	-	-	-	-	-	-	-
Other, net
109	15	-10	-23	-5	31	35	31	9	1	0	5	-1	-2	-3	-0	-12	-8	-5	-8	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from disposal of non-current investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from disposal of property, plant and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Returns of equity investments and proceeds from short term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Net cash provided by/(used in) investing activities
1,458	-750	-678	-700	-763	-854	-12,629	-18,092	-17,865	-17,970	-6,116	-5,619	-5,590	-5,326	-5,517	-4,030	-4,046	-4,019	-3,929	-360	-376	-370	-358	-271	-262	-183	-791	-809	-727	-1,400	-814	-797	-918	-361	-248	-322	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings
4,710	4,775	3,258	4,236	3,962	15,660	27,540	32,443	31,852	19,730	7,835	3,760	3,650	2,925	2,370	2,310	2,310	2,310	2,170	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of revolving line of credit, long term and short term borrowings
9,985	8,415	7,295	7,681	7,435	18,431	17,234	16,404	15,257	3,080	3,570	3,110	2,486	1,741	1,346	1,461	1,461	1,251	650	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of debt acquired through business combinations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	551	551	551	533	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from ViroPharma call options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	346	346	346	346	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt issuance costs
-	-	-	-	-	-	-	172	191	132	114	24	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contingent consideration payments
-	-	-	-	-	-	-	-	-	-	-	-	-	9	9	15	15	15	15	14	14	14	11	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments to acquire shares (in USD)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243	395	422	276	205	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment under building finance obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	2	3	4	4	0	0	0
Excess tax benefit associated with exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	41	36	29	13	11	11	10	40	46	47	57	31	20	20	10	6	0	0	0	-	-	-	-
Proceeds from issuance of stock for share-based compensation arrangements
222	188	132	134	124	248	211	169	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	11	13	15	16	14	0	0	0
Other, net
-26	-10	-13	-27	-20	-74	-59	-38	-117	-56	-68	-69	45	39	39	39	-3	0	-6	-7	-6	-8	-4	-3	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-5,798	-3,785	-4,199	-3,619	-3,646	-2,933	10,206	15,825	16,284	16,300	3,947	439	1,042	1,083	918	554	549	745	1,073	-344	-483	-512	-352	-244	-107	-155	-169	-195	-191	-98	-96	-99	-68	-72	-22	-28	0	0	0
Effect of foreign exchange rate changes on cash and cash equivalents
-11	-5	6	7	9	6	2	0	-3	-4	-0	-3	-4	-8	-9	-9	-6	1	-4	-0	-0	-6	-4	-5	-5	-3	-0	0	-4	-9	-5	-6	-1	12	8	4	0	0	0
Net decrease in cash, cash equivalents, and restricted cash
-24	-17	-63	-56	-510	-421	308	393	683	629	-5	-2,846	-422	-89	-64	743	-1,218	-1,148	-1,311	757	364	189	571	862	1,045	968	167	69	83	-537	54	51	-139	419	366	280	0	0	0
Supplemental information:
Interest paid
-	0	598	-	-	439	378	284	230	121	28	20	35	16	16	14	4	20	31	29	33	34	34	34	35	34	33	33	31	29	25	25	26	27	34	31	0	0	0
Income taxes repaid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes paid, net
745	773	546	524	383	353	364	431	0	0	0	-	-	-	-	-194	201	258	276	290	309	327	265	199	156	206	309	286	302	271	245	329	309	309	363	223	0	0	0
Equity in Vertex Pharmaceuticals, Inc. ("Vertex") received as part consideration for disposal of non-current investment in Virochem Pharma, Inc. ("Virochem")
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	0	0	0	-	-	-	-
Building financing obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	0	0	0